`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`
`CELLTRION, INC.,
`Petitioner,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`_____________________________
`
`IPR2024-00260
`U.S. Patent No. 11,253,572
`_____________________________
`
`MOTION FOR JOINDER UNDER 35 U.S.C. § 315(c)
`AND 37 C.F.R. §§42.22 AND 42.122(b)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I.
`
`STATEMENT OF THE PRECISE RELIEF REQUESTED
`
`Petitioner, Celltrion, Inc. (“Celltrion” or “Petitioner”), respectfully requests
`
`joinder of the concurrently filed petition for inter partes review of U.S. Patent No.
`
`11,253,572 (“the ’572 Patent”) (IPR2024-00260) with Samsung Bioepis Co., Ltd.,
`
`v. Regeneron Pharms., Inc., IPR2023-00884 (P.T.A.B.), filed April 27, 2023, and
`
`instituted on November 17, 2023 (“the Samsung IPR”). (See IPR2023-00884,
`
`Paper 13). Celltrion has conferred with Samsung Bioepis (“Samsung”), and
`
`Samsung does not oppose this Motion for Joinder.
`
`The instant Petition is substantially the same as the Samsung IPR: it involves
`
`the same patent, same claims, same grounds of unpatentability, and the same
`
`evidence1 (including the same prior art combinations) as the Samsung IPR. If
`
`joined, Celltrion will assume a “silent understudy” role and will not take an active
`
`role in the inter partes review proceeding unless Samsung ceases to participate in
`
`the instituted IPR. Thus, the proposed joinder will neither unduly complicate the
`
`
`1 Celltrion filed a declaration by its expert, Dr. Christine Kay, as part of its petition
`
`materials. The conclusions and underlying reasoning of the experts are identical,
`
`and therefore present no additional burden on the part of the Patent Owners to
`
`address. Dr. Kay will also not have an active role in the IPR unless Samsung
`
`ceases to participate.
`
`-1-
`
`
`
`Samsung IPR nor delay its schedule. As such, the joinder will promote judicial
`
`efficiency in determining patentability in the Samsung IPR without prejudice to
`
`Patent Owner.
`
`Although Celltrion is not otherwise time barred pursuant to 37 C.F.R.
`
`§ 42.101(b), this Motion for Joinder, and accompanying Petition, are timely
`
`because they are filed less than one month after a decision instituting trial in the
`
`Samsung IPR. 37 C.F.R. § 42.122(b) (“no later than one month after the institution
`
`date of any inter partes review for which joinder is requested.”). Accordingly,
`
`Celltrion respectfully requests that the Board grant this Motion for Joinder.
`
`II.
`
`STATEMENT OF REASONS FOR RELIEF REQUESTED
`
`A. Legal Standard
`
`The Leahy-Smith America Invents Act (AIA) permits joinder of inter partes
`
`review (IPR) proceedings. Joinder is governed by 35 U.S.C. § 315(c), which states:
`
`(c)
`
`JOINDER. – If the Director institutes an inter partes review, the
`
`Director, in his or her discretion, may join as a party to that inter
`
`partes review any person who properly files a petition under section
`
`311 that the Director, after receiving a preliminary response under
`
`section 313 or the expiration of the time for filing such a response,
`
`determines warrants the institution of an inter partes review under
`
`section 314.
`
`-2-
`
`
`
`The AIA’s legislative history makes clear that joinder is to be liberally
`
`granted. 157 Cong. Rec. S1376 (daily ed. Mar. 8, 2011) (statement of Sen. Kyl).
`
`As joinder should be liberally granted, the factors General Plastic Indus. Co. Ltd.
`
`v. Canon Kabushiki Kaisha, IPR2016-01357, Pap. 19 at 16 (Sept. 6, 2017) favor
`
`institution, as Celltrion has not previously filed a petition challenging the same
`
`claims of the ’572 patent.2
`
`A motion for joinder should “(1) set forth the reasons why joinder is
`
`appropriate; (2) identify any new grounds of unpatentability asserted in the
`
`petition; (3) explain what impact (if any) joinder would have on the trial schedule
`
`for the existing review; and (4) address specifically how briefing and discovery
`
`may be simplified.” Dell Inc. v. Network-1 Sec. Solutions, Inc., IPR2013-00385,
`
`Paper 17 (PTAB July 29, 2013); Hyundai Motor Co. v. Am. Vehicular Scis. LLC,
`
`IPR2014-01543, Paper 11, at 3 (Oct. 24, 2014); Macronix Int’l Co. v. Spansion,
`
`
`2 The other factors are either also positive or neutral. For example, Factor 6,
`
`which is the “finite resources of the Board,” favors institution as Celltrion is
`
`advancing the same challenges, arguments, and evidence relied upon in the
`
`Samsung IPR. For the same reason, Regeneron’s Preliminary Response was not
`
`used as a roadmap for this Petition. And as discussed in the Motion, joinder would
`
`have no impact on the trial schedule for the Samsung IPR.
`
`-3-
`
`
`
`IPR2014-00898, Paper 15, at 4 (Aug. 13, 2014) (quoting Kyocera Corp. v.
`
`Softview LLC, IPR2013-00004, Paper 15, at 4 (April 24, 2013)).
`
`B. Celltrion’s Motion for Joinder is Timely
`
`A motion for joinder is timely if the moving party files within one month of
`
`institution of the inter partes review for which joinder is requested. 37
`
`C.F.R. 42.122(b). Because Celltrion files this motion within one month after a
`
`decision on the institution of the Samsung IPR, this motion is timely.
`
`C.
`
`Joinder is appropriate
`
`Joinder is appropriate because Celltrion’s Petition does not raise any new
`
`grounds of unpatentability and does “not present issues that might complicate or
`
`delay” the Samsung IPR. See Enzymotec Ltd. v. Neptune Techs & Bioresources,
`
`Inc., IPR2014-00556, Paper 19 (PTAB July 9, 2014). Celltrion’s Petition is
`
`substantially identical to the petition in the Samsung IPR, challenging the same
`
`claims of the ’572 Patent on the same grounds and relying on the same testimony
`
`from an expert declarant. Thus, the only difference between Celltrion’s Petition
`
`and the petition filed in the Samsung IPR are the sections on Real Party-In-Interest,
`
`Related Matters, and Counsel, which have been appropriately updated.
`
`Joinder would, therefore, have little, if any, impact on the Samsung IPR, the
`
`schedule would not be affected, no additional briefing or discovery would be
`
`-4-
`
`
`
`required, and no additional burdens would be placed on any party or the PTAB, as
`
`detailed below.
`
`1.
`
`No New Grounds of Unpatentability in the Petition
`
`Celltrion’s Petition does not assert any new grounds of unpatentability. It
`
`challenges the same claims (1-30) of the ’572 Patent based on the same arguments
`
`and analysis, prior art, evidence, and eleven grounds of unpatentability as the
`
`Samsung IPR. See, e.g., Hyundai, IPR2014-01543, Paper 11, at 2-4; Dell,
`
`IPR2013-00385, Paper 17, at 6-10.
`
`2.
`
`No Impact on the Schedule For the Existing IPR Proceeding
`
`Because Celltrion’s Petition raises no new grounds of unpatentability, and
`
`because a Scheduling Order has been established for the Samsung IPR less than
`
`one month ago, joinder should have no impact on the schedule of the Samsung
`
`IPR. See LG v. Memory Integrity, LLC., IPR2015-01353, Paper 11, at 6 (Oct. 5,
`
`2015) (granting IPR and motion for joinder where “joinder should not necessitate
`
`any additional briefing or discovery from Patent Owner beyond that already
`
`required in [the original IPR]”). Celltrion will adhere to all applicable deadlines set
`
`in the Scheduling Order for the Samsung IPR.
`
`As discussed further below, Celltrion is willing to limit its participation in
`
`this proceedings to a “silent understudy.” In the event that the Samsung IPR is
`
`terminated with respect to the Samsung Petitioner, only then does Celltrion intend
`
`-5-
`
`
`
`to “step into the shoes” of the dismissed petitioner and materially participate in the
`
`joined proceedings. Accordingly, for the reasons stated above, joinder of Celltrion
`
`to the Samsung IPR will not affect the Board’s ability to complete its review and
`
`final decision within the statutory time limits under 35 U.S.C. § 316(a)(11) and 37
`
`C.F.R. § 42.100(c).
`
`3.
`
`Briefing and Discovery Will be Simplified
`
`As a “silent understudy,” Celltrion agrees that, if joined, the following
`
`conditions will apply so long as Samsung remains an active party, as previously
`
`approved by the Board in other joinder circumstances:
`
`(a)
`
`all filings by Celltrion in the joined proceeding be consolidated with
`
`the filings of Samsung, unless a filing solely concerns issues that do not involve
`
`Samsung;
`
`(b) Celltrion shall not be permitted to raise any new grounds not instituted
`
`by the Board in the Samsung IPR, or introduce any argument not already
`
`introduced by Samsung;
`
`(c) With regard to taking of testimony, Celltrion will abide by 37 C.F.R.
`
`§ 42.53 or any agreement between the Patent Owner and Samsung. See DRL
`
`Pharms. Inc. v. Novartis AG, IPR2015-00268, Paper 17, at 5-6 (PTAB Apr. 10,
`
`2015) (finding the same proposed limitations “are consistent with the ‘understudy’
`
`role that Petitioner agrees to assume, as well as Petitioner’s assertion that its
`
`-6-
`
`
`
`presence would not require introducing any additional arguments, briefing, or
`
`discovery.”). Celltrion is also willing to abide by any additional conditions the
`
`Board deems appropriate.
`
`4.
`
`No Prejudice to Patent Owner
`
`Joinder of Petitioner to the Samsung IPR will not create any additional
`
`burden on the Patent Owner. The Patent Owner need not expend any additional
`
`resources above and beyond those required in the current Samsung IPR. Moreover,
`
`joinder eliminates the need for the Patent Owner to participate in multiple,
`
`staggered inter partes review proceedings instituted upon identical grounds of
`
`unpatentability.3
`
`
`3 The argument that joinder may theoretically frustrate settlement between
`
`Samsung and Patent Owner is not a basis to deny joinder because that same
`
`possibility exists in every joinder situation. Global Foundries U.S. Inc. v . Godo
`
`Kaisha IP Bridge 1, IPR2017-00925 and IPR2017-00926, Paper 13, at 10 (June 9,
`
`2017)
`
`-7-
`
`
`
`III. Conclusion
`
`For the foregoing reasons, Celltrion respectfully requests that its Petition for
`
`inter partes review of the ’572 patent be granted and that the proceeding be joined
`
`with IPR2023-00884.
`
`Dated: December 14, 2023
`
`
`
`
`
`
`Respectfully submitted,
`
` / Lora M. Green /
`Lora M. Green, Lead Counsel
`Reg. No. 43,541
`
`
`
`
`
`-8-
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), this is to certify that I
`
`caused to be served a true and correct copy of the foregoing Motion for Joinder by
`
`overnight courier (Federal Express), on this 14th day of December, 2023, on the
`
`Patent Owner at the correspondence address of the Patent Owner as follows:
`
`191459 – A&P – Regeneron (Prosecution)
`601 Massachusetts Ave., N.W.
`Washington, DC 20001-3743
`
`Regeneron – Bozicevic Field & Francis LLP 201
`Redwood Shores Parkway
`Suite 200
`Redwood City, CA 94065
`
`Regeneron Pharmaceuticals, Inc.
` 770 Old Saw Mill River Road
`Tarrytown, NY 10591
`
`And additional copies have been delivered to counsel for Patent Owner in
`
`IPR2023-00884, as follows:
`
`Adam R. Brausa
`Rebecca Weires
`MORRISON & FOERSTER LLP
`abrausa@mofo.com
`rweires@mofo.com
`regeneron-mofo-ipr@mofo.com
`
`And to counsel for Petitioner in IPR2023-00884, as follows:
`
`Raymond N. Nimrod
`Matthew A. Traupman
`Landon Andrew Smith
`
`-9-
`
`
`
`QUINN EMANUEL URQUHART & SULLIVAN LLP
`raynimrod@quinnemanuel.com
`matthewtraupman@quinnemanuel.com
`landonsmith@quinnemanuel.com
`qe-samsungbioepis@quinnemanuel.com
`
`
`
`DATED: December 14, 2023
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`/Ashley F. Cheung/
`Paralegal for
`Petitioner’s Counsel
`
`
`
`-10-
`
`